Diagnostic Significance of Urinary Podocalyxin in Patients with Diabetic Nephropathy
IOSR Journal of Dental and Medical Sciences · 2026-04 · 25 (4) · 81-88
DOI: 10.9790/0853-2504018188 ↗Kurz gefasst
Fachartikel in der Zeitschrift IOSR Journal of Dental and Medical Sciences, 2026-04. Verfasst von Dr. Taslima Akter.
Abstract (Originalsprache)
Background
Diabetic nephropathy is one of the primary causes of end-stage renal disease in the world, and renal disease diagnosis is a clinical issue. The traditional biomarkers, like microalbuminuria, reveal the damage to the kidney at a very late stage. This study aimed to assess the clinical importance of urinary podocalyxin in diabetic nephropathy at different stages of albuminuria.
Methods
This cross-sectional study was conducted at Bangladesh Medical University from March 2024 to February 2025 on 50 diabetic patients and subdivided them into Group I (microalbuminuria, n=25) and Group II (normoalbuminuria, n=25). ELISA was used to measure urinary podocalyxin; standard tests were used to measure HbA1c, urinary microalbumin, and serum creatinine. The ROC curve analysis was used to examine the diagnostic performance. Data were entered and analyzed using SPSS version 26.
Results
Group I had a very high level of urinary podocalyxin than Group II because of (7.89 ±1.13 vs. 5.11±0.99 ng/mL, p
Zitieren
APA
Akter, D. T. (2026). Diagnostic Significance of Urinary Podocalyxin in Patients with Diabetic Nephropathy. IOSR Journal of Dental and Medical Sciences, 25(4), 81-88. https://doi.org/10.9790/0853-2504018188
Vancouver
Akter DT. Diagnostic Significance of Urinary Podocalyxin in Patients with Diabetic Nephropathy. IOSR Journal of Dental and Medical Sciences. 2026;25(4):81-88. doi:10.9790/0853-2504018188
BibTeX
@article{Akter2026,
author = {Akter, Dr. Taslima},
title = {Diagnostic Significance of Urinary Podocalyxin in Patients with Diabetic Nephropathy},
journal = {IOSR Journal of Dental and Medical Sciences},
year = {2026},
volume = {25},
number = {4},
pages = {81--88},
doi = {10.9790/0853-2504018188}
}
EUVIMED